Abvc Biopharma, Inc.
ABVC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173313
No open-market purchases or sales by Abvc Biopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.72M in total; no superinvestor holds it.
Other share classesECOC
Holders of 5% or more of ABVC
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Abvc Biopharma, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Jiang Eugene | 13D/A | 18.50%131.2K shares | +1.10 ppfrom 17.40% | Jun 3, 20252 filings | Jul 15, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
4 Schedule 13D and 13G filings on Abvc Biopharma, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 20255:08 PM ET | Lind Global Fund II LPand 2 others | 13G/A | 3.20%557.1K shares | −6.70 ppfrom 9.90%Below 5% | Jun 30, 2025 | SEC |
| Jul 15, 20254:30 PM ET | Jiang Eugene | 13D/A | 18.50%131.2K shares | +1.10 ppfrom 17.40% | Jul 10, 2025 | SEC |
| Jun 3, 20254:01 PM ET | Jiang Eugene | 13D | 17.40%131.2K shares | New | May 13, 2025 | SEC |
| Feb 14, 20255:13 PM ET | Lind Global Fund II LPand 2 others | 13G/A | 9.90%1.32M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Abvc Biopharma, Inc. shares.
No Form 144 notices for Abvc Biopharma, Inc. are on file.